Spondyloarthritis & psoriatic arthritis
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
Authors' conclusion
Risankizumab treatment resulted in greater improvements in HRQoL, fatigue, pain and work productivity in patients with active PsA who have csDMARD-IR, when compared with placebo.
Study context
- Population
- Adults with active PsA and inadequate response or intolerance to csDMARD (csDMARD-IR)
- Participants
- 964 adults
- Comparison
- Risankizumab 150 mg vs placebo
- Primary endpoint
- Least squares (LS) mean change from baseline in health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) (SF-36, FACIT-Fatigue, EQ-5D-5L, Patient's Assessment of Pain, PtGA, WPAI-PsA)
- Follow-up
- Week 24
Methodological detailsrandomized (1:1)
- Randomized (1:1)
Primary result
As reported in the abstract
LS mean change from baseline in PROs, risankizumab vs placebo
Differences between groups in SF-36 physical and mental component summary, FACIT-Fatigue, EQ-5D-5L, Patient's Assessment of Pain, Patient's Global Assessment (PtGA) and all eight SF-36 domains
all nominal P < 0.001
Differences between groups in Work Productivity and Activity Impairment-PsA (WPAI-PsA) presenteeism, overall work impairment and activity impairment
all nominal P < 0.01
Original publication
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology (Oxford). Published 8 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →